The analysis of the main characteristics of the pharmaceutical industry worldwide and market aspects of that industry in Brazil leads us to consider a high share of external dependency and oligopolization. This situation is not peculiar to our country, but is rather a global trend. Recent Government initiatives in Brazil, aiming at reducing that dependency, associated with the critical aspects regarding the prices and costs of drugs as compared to international prices, are the background that support the proposal of evaluating generic drugs as an alternative for Brazilian market. One of the most striking aspect is the verification of overpricing of raw materials as demonstrated by "transfer prices", a practice that has been observed in several countries. Analysing international concepts dealing with generic drugs, generic names and pharmaceutical equivalence, based on World Health Organization recomendations and evaluating the experiences of different countries, several actions are proposed in order to gradually enforce a policy of generic drugs, bioequivalent and interchangeable, as a possible regulatory mechanisms for Brazil.
Generic Drugs; Drug Policies and Health; Drug Market; Pharmaceutical Industry
